FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570221166> ?p ?o ?g. }

• W2570221166 endingPage "245" @default.
• W2570221166 startingPage "239" @default.
• W2570221166 abstract "Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection Liwen Fan,1 Haitang Yang,1,2 Feng Yao,1 Yang Zhao,1 Haiyong Gu,1 Ke Han,1 Heng Zhao1 1Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Division of General Thoracic Surgery, Inselspital University Hospital Bern, Bern, Switzerland Purpose: The therapeutic efficacy of targeted therapy for adenosquamous carcinoma (ASC) of the lung remains unclear and the role of epidermal growth factor receptor (EGFR) testing in patients with ASC also remains controversial. We aimed to analyze the efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs) in ASC. Methods: Clinical records of patients with ASC who received treatment with EGFR-TKIs between January 2006 and December 2014 at two institutions were retrospectively reviewed. Results: A total of 27 EGFR mutation-positive patients with ASC who received TKI therapy were enrolled in this study. EGFR mutations included a deletion in exon 19 in 15 cases and a point mutation at codon 858 (L858R) in exon 21 in 12 cases. Among the 27 ASC patients who received treatment with EGFR-TKIs, nine had a partial response and 11 achieved stable disease, accounting for a disease control rate of 74.1% (20/27). The median postoperative overall survival (OS) of the EGFR-mutant patients who received TKI therapy was 39 months (95% confidence interval [CI]: 25.6–52.4). The median progression-free survival for EGFR mutation-positive patients was 15 months (95% CI: 12.9–17.1), and the median relapse OS was 19 months (95% CI: 0.9–37.1). In addition, the 3- and 5-year postoperative survival rate was 51.9% and 15.3%, respectively. Conclusion: ASC patients harboring EGFR mutations had a good response to TKI therapy. Routine EGFR testing for ASCs was recommended. Further studies on TKI therapy versus chemotherapy alone for EGFR-mutant ASCs are required. Keywords: adenosquamous carcinoma of the lung, epidermal growth factor receptor tyrosine kinase inhibitors, mutation, survival" @default.
• W2570221166 created "2017-01-13" @default.
• W2570221166 creator A5003539049 @default.
• W2570221166 creator A5009303429 @default.
• W2570221166 creator A5012437062 @default.
• W2570221166 creator A5024958140 @default.
• W2570221166 creator A5051138947 @default.
• W2570221166 creator A5059434741 @default.
• W2570221166 creator A5084929058 @default.
• W2570221166 date "2017-01-01" @default.
• W2570221166 modified "2023-09-24" @default.
• W2570221166 title "Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection" @default.
• W2570221166 cites W1538865092 @default.
• W2570221166 cites W1627569348 @default.
• W2570221166 cites W1952055580 @default.
• W2570221166 cites W1964681864 @default.
• W2570221166 cites W1969855950 @default.
• W2570221166 cites W1988734083 @default.
• W2570221166 cites W1990119280 @default.
• W2570221166 cites W1991696266 @default.
• W2570221166 cites W2005724920 @default.
• W2570221166 cites W2006742244 @default.
• W2570221166 cites W2007602495 @default.
• W2570221166 cites W2025404610 @default.
• W2570221166 cites W2033157701 @default.
• W2570221166 cites W2037372171 @default.
• W2570221166 cites W2037791152 @default.
• W2570221166 cites W2056659899 @default.
• W2570221166 cites W2088720324 @default.
• W2570221166 cites W2089767548 @default.
• W2570221166 cites W2111662961 @default.
• W2570221166 cites W2119994930 @default.
• W2570221166 cites W2122553809 @default.
• W2570221166 cites W2129360604 @default.
• W2570221166 cites W2129590156 @default.
• W2570221166 cites W2132157071 @default.
• W2570221166 cites W2137043950 @default.
• W2570221166 cites W2153942353 @default.
• W2570221166 cites W2154662831 @default.
• W2570221166 cites W2166084034 @default.
• W2570221166 cites W2168045554 @default.
• W2570221166 cites W2210071992 @default.
• W2570221166 cites W2292890953 @default.
• W2570221166 cites W2344620905 @default.
• W2570221166 doi "https://doi.org/10.2147/ott.s114451" @default.
• W2570221166 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5229167" @default.
• W2570221166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28123305" @default.
• W2570221166 hasPublicationYear "2017" @default.
• W2570221166 type Work @default.
• W2570221166 sameAs 2570221166 @default.
• W2570221166 citedByCount "18" @default.
• W2570221166 countsByYear W25702211662018 @default.
• W2570221166 countsByYear W25702211662019 @default.
• W2570221166 countsByYear W25702211662020 @default.
• W2570221166 countsByYear W25702211662021 @default.
• W2570221166 countsByYear W25702211662023 @default.
• W2570221166 crossrefType "journal-article" @default.
• W2570221166 hasAuthorship W2570221166A5003539049 @default.
• W2570221166 hasAuthorship W2570221166A5009303429 @default.
• W2570221166 hasAuthorship W2570221166A5012437062 @default.
• W2570221166 hasAuthorship W2570221166A5024958140 @default.
• W2570221166 hasAuthorship W2570221166A5051138947 @default.
• W2570221166 hasAuthorship W2570221166A5059434741 @default.
• W2570221166 hasAuthorship W2570221166A5084929058 @default.
• W2570221166 hasBestOaLocation W25702211661 @default.
• W2570221166 hasConcept C121608353 @default.
• W2570221166 hasConcept C126322002 @default.
• W2570221166 hasConcept C143998085 @default.
• W2570221166 hasConcept C2776256026 @default.
• W2570221166 hasConcept C2776512503 @default.
• W2570221166 hasConcept C2778087573 @default.
• W2570221166 hasConcept C2779438470 @default.
• W2570221166 hasConcept C2781182431 @default.
• W2570221166 hasConcept C71924100 @default.
• W2570221166 hasConcept C90924648 @default.
• W2570221166 hasConceptScore W2570221166C121608353 @default.
• W2570221166 hasConceptScore W2570221166C126322002 @default.
• W2570221166 hasConceptScore W2570221166C143998085 @default.
• W2570221166 hasConceptScore W2570221166C2776256026 @default.
• W2570221166 hasConceptScore W2570221166C2776512503 @default.
• W2570221166 hasConceptScore W2570221166C2778087573 @default.
• W2570221166 hasConceptScore W2570221166C2779438470 @default.
• W2570221166 hasConceptScore W2570221166C2781182431 @default.
• W2570221166 hasConceptScore W2570221166C71924100 @default.
• W2570221166 hasConceptScore W2570221166C90924648 @default.
• W2570221166 hasLocation W25702211661 @default.
• W2570221166 hasLocation W25702211662 @default.
• W2570221166 hasLocation W25702211663 @default.
• W2570221166 hasLocation W25702211664 @default.
• W2570221166 hasOpenAccess W2570221166 @default.
• W2570221166 hasPrimaryLocation W25702211661 @default.
• W2570221166 hasRelatedWork W1974610627 @default.
• W2570221166 hasRelatedWork W1976268611 @default.
• W2570221166 hasRelatedWork W2005973176 @default.
• W2570221166 hasRelatedWork W2165426291 @default.
• W2570221166 hasRelatedWork W2186047679 @default.
• W2570221166 hasRelatedWork W2496807276 @default.
• W2570221166 hasRelatedWork W2540520719 @default.

• next